361 related articles for article (PubMed ID: 26589238)
41. Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in Japan.
Kashiwagi A; Shoji S; Onozawa S; Kosakai Y; Waratani M; Ito Y
J Diabetes Investig; 2022 Jul; 13(7):1175-1189. PubMed ID: 35243799
[TBL] [Abstract][Full Text] [Related]
42. Adverse Effects Associated With Newer Diabetes Therapies.
Akiyode OF; Adesoye AA
J Pharm Pract; 2017 Apr; 30(2):238-244. PubMed ID: 26169212
[TBL] [Abstract][Full Text] [Related]
43. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study.
Fisher A; Fralick M; Filion KB; Dell'Aniello S; Douros A; Tremblay É; Shah BR; Ronksley PE; Alessi-Severini S; Hu N; Bugden SC; Ernst P; Lix LM;
Diabetes Obes Metab; 2020 Sep; 22(9):1648-1658. PubMed ID: 32383792
[TBL] [Abstract][Full Text] [Related]
44. Glyxambi--a new combination for type 2 diabetes.
Med Lett Drugs Ther; 2015 Apr; 57(1467):65-6. PubMed ID: 25897551
[No Abstract] [Full Text] [Related]
45. The epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors.
Huang W; Whitelaw J; Kishore K; Neto AS; Holmes NE; Marhoon N; Bellomo R; Ekinci EI
J Diabetes Complications; 2023 Aug; 37(8):108522. PubMed ID: 37311358
[TBL] [Abstract][Full Text] [Related]
46. Glucagon and heart in type 2 diabetes: new perspectives.
Ceriello A; Genovese S; Mannucci E; Gronda E
Cardiovasc Diabetol; 2016 Aug; 15(1):123. PubMed ID: 27568179
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
J Diabetes Investig; 2018 Jul; 9(4):893-902. PubMed ID: 28950431
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
Frandsen CS; Madsbad S
Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
[TBL] [Abstract][Full Text] [Related]
49. [Recommendations of the main clinical practice guidelines].
Miravet I Jiménez S
Semergen; 2018 Jun; 44 Suppl 1():3-9. PubMed ID: 30322471
[TBL] [Abstract][Full Text] [Related]
50. Cardiovascular safety of therapies for type 2 diabetes.
Gupta P; White WB
Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
[TBL] [Abstract][Full Text] [Related]
51. Distinguishing among incretin-based therapies. Introduction.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
[TBL] [Abstract][Full Text] [Related]
52. In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control.
Watanabe T; Temma Y; Okada J; Yamada E; Saito T; Osaki A; Shimda Y; Matsumoto S; Horiguchi K; Ishida E; Kondo Y; Okada K; Takamizawa T; Nakajima Y; Ozawa A; Okada S; Horigome M; Yamada M
Endocr J; 2021 May; 68(5):599-603. PubMed ID: 33408313
[TBL] [Abstract][Full Text] [Related]
53. Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Kuhn A; Park J; Ghazi A; Aroda VR
Curr Cardiol Rep; 2017 Mar; 19(3):25. PubMed ID: 28251513
[TBL] [Abstract][Full Text] [Related]
54. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Toth PP
Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
[TBL] [Abstract][Full Text] [Related]
55. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
Paolisso G; Monami M; Marfella R; Rizzo MR; Mannucci E
Adv Ther; 2012 Mar; 29(3):218-33. PubMed ID: 22411425
[TBL] [Abstract][Full Text] [Related]
56. [Significance of combination therapy with an insulin sensitizer and a DPP-4(dipeptidyl peptidase-4) inhibitor].
Yasuda T; Shimomura I
Nihon Rinsho; 2013 Mar; 71(3):555-62. PubMed ID: 23631252
[TBL] [Abstract][Full Text] [Related]
57. Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
Okahata S; Sakamoto K; Mitsumatsu T; Kondo Y; Tanaka S; Shiba T
Diabetes Obes Metab; 2019 Feb; 21(2):388-392. PubMed ID: 30146790
[TBL] [Abstract][Full Text] [Related]
58. Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes?
McIntyre HF; Grant P
Br J Hosp Med (Lond); 2007 Nov; 68(11):599-602. PubMed ID: 18087847
[TBL] [Abstract][Full Text] [Related]
59. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Bailey CJ; Green BD; Flatt PR
Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
[TBL] [Abstract][Full Text] [Related]
60. New forms of insulin and insulin therapies for the treatment of type 2 diabetes.
Cahn A; Miccoli R; Dardano A; Del Prato S
Lancet Diabetes Endocrinol; 2015 Aug; 3(8):638-52. PubMed ID: 26051044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
